-
公开(公告)号：US20080311150A1
公开(公告)日：2008-12-18
申请号：US12079888
申请日：2008-03-28
CPC分类号： C07H21/02 , A61K2039/5258 , C07H21/04 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2740/13023 , C12N2740/13043 , C12N2740/13045 , C12N2770/24222 , C12N2770/24234 , C12N2810/609 , C12Q1/707
摘要： The present invention concerns a modified nucleic acid molecule comprising a nucleotide sequence coding for a full length hepatitis C virus (HCV) glycoprotein selected from the group consisting of E1 glycoprotein and E1/E2 glycoprotein heterodimer, this molecule having at least one nucleotide alteration, wherein, due to this alteration, at least one RNA splice site selected from the group consisting of RNA splice acceptor and RNA splice donor sites is eliminated from the coding sequence. The invention is also directed to methods for expressing on the surface of a cell and a pseudovirion an HCV glycoprotein, wherein the majority of the glycoprotein is full length. The invention further provides a cell and a pseudovirion expressing such glycoprotein. The invention still further provides a method for determining whether an agent inhibits HCV fusion with and entry into a target cell. The invention also provides an agent that inhibits HCV fusion with and entry into a target cell. The invention further provides methods for treating a subject afflicted with an HCV-associated disorder, for preventing an HCV infection in a subject, and for inhibiting in a subject the onset of an HCV-associated disorder.
摘要翻译： 本发明涉及一种修饰的核酸分子，其包含编码选自E1糖蛋白和E1 / E2糖蛋白异源二聚体的全长丙型肝炎病毒（HCV）糖蛋白的核苷酸序列，该分子具有至少一个核苷酸改变，其中 由于这种改变，从编码序列中消除了选自RNA剪接受体和RNA剪接供体位点的至少一个RNA剪接位点。 本发明还涉及用于在细胞表面和假病毒表达HCV糖蛋白的方法，其中大部分糖蛋白是全长的。 本发明还提供了表达这种糖蛋白的细胞和假病毒。 本发明还提供了一种用于确定药物是否抑制HCV融合并进入靶细胞的方法。 本发明还提供了抑制HCV融合并进入靶细胞的药剂。 本发明进一步提供了治疗患有HCV相关病症的受试者，用于预防受试者中的HCV感染以及用于在受试者中抑制HCV相关病症发作的方法。
-
公开(公告)号：US20050266400A1
公开(公告)日：2005-12-01
申请号：US10985205
申请日：2004-11-09
IPC分类号： A61K39/00 , C07H21/02 , C07H21/04 , C07K14/18 , C12N20060101 , C12N7/00 , C12N7/01 , C12Q1/68 , C12Q1/70
CPC分类号： C07H21/02 , A61K2039/5258 , C07H21/04 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2740/13023 , C12N2740/13043 , C12N2740/13045 , C12N2770/24222 , C12N2770/24234 , C12N2810/609 , C12Q1/707
摘要： The present invention concerns a modified nucleic acid molecule comprising a nucleotide sequence coding for a full length hepatitis C virus (HCV) glycoprotein selected from the group consisting of E1 glycoprotein and E1/E2 glycoprotein heterodimer, this molecule having at least one nucleotide alteration, wherein, due to this alteration, at least one RNA splice site selected from the group consisting of RNA splice acceptor and RNA splice donor sites is eliminated from the coding sequence. The invention is also directed to methods for expressing on the surface of a cell and a pseudovirion an HCV glycoprotein, wherein the majority of the glycoprotein is full length. The invention further provides a cell and a pseudovirion expressing such glycoprotein. The invention still further provides a method for determining whether an agent inhibits HCV fusion with and entry into a target cell. The invention also provides an agent that inhibits HCV fusion with and entry into a target cell. The invention further provides methods for treating a subject afflicted with an HCV-associated disorder, for preventing an HCV infection in a subject, and for inhibiting in a subject the onset of an HCV-associated disorder.
摘要翻译： 本发明涉及一种修饰的核酸分子，其包含编码选自E1糖蛋白和E1 / E2糖蛋白异二聚体的全长丙型肝炎病毒（HCV）糖蛋白的核苷酸序列，该分子具有至少一个核苷酸改变，其中 由于这种改变，从编码序列中消除了选自RNA剪接受体和RNA剪接供体位点的至少一个RNA剪接位点。 本发明还涉及用于在细胞表面和假病毒表达HCV糖蛋白的方法，其中大部分糖蛋白是全长的。 本发明还提供了表达这种糖蛋白的细胞和假病毒。 本发明还提供了一种用于确定药物是否抑制HCV融合并进入靶细胞的方法。 本发明还提供了抑制HCV融合并进入靶细胞的药剂。 本发明进一步提供了治疗患有HCV相关病症的受试者，用于预防受试者中的HCV感染以及用于在受试者中抑制HCV相关病症发作的方法。
-
公开(公告)号：US07361503B2
公开(公告)日：2008-04-22
申请号：US10985205
申请日：2004-11-09
IPC分类号： C12N15/63
CPC分类号： C07H21/02 , A61K2039/5258 , C07H21/04 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2740/13023 , C12N2740/13043 , C12N2740/13045 , C12N2770/24222 , C12N2770/24234 , C12N2810/609 , C12Q1/707
摘要： The present invention concerns a modified nucleic acid molecule comprising a nucleotide sequence coding for a full length hepatitis C virus (HCV) glycoprotein selected from the group consisting of E1 glycoprotein and E1/E2 glycoprotein heterodimer, this molecule having at least one nucleotide alteration, wherein, due to this alteration, at least one RNA splice site selected from the group consisting of RNA splice acceptor and RNA splice donor sites is eliminated from the coding sequence. The invention is also directed to methods for expressing on the surface of a cell and a pseudovirion an HCV glycoprotein, wherein the majority of the glycoprotein is full length. The invention further provides a cell and a pseudovirion expressing such glycoprotein. The invention still further provides a method for determining whether an agent inhibits HCV fusion with and entry into a target cell. The invention also provides an agent that inhibits HCV fusion with and entry into a target cell. The invention further provides methods for treating a subject afflicted with an HCV-associated disorder, for preventing an HCV infection in a subject, and for inhibiting in a subject the onset of an HCV-associated disorder.
摘要翻译： 本发明涉及一种修饰的核酸分子，其包含编码选自E1糖蛋白和E1 / E2糖蛋白异二聚体的全长丙型肝炎病毒（HCV）糖蛋白的核苷酸序列，该分子具有至少一个核苷酸改变，其中 由于这种改变，从编码序列中消除了选自RNA剪接受体和RNA剪接供体位点的至少一个RNA剪接位点。 本发明还涉及用于在细胞表面和假病毒表达HCV糖蛋白的方法，其中大部分糖蛋白是全长的。 本发明还提供了表达这种糖蛋白的细胞和假病毒。 本发明还提供了一种用于确定药物是否抑制HCV融合并进入靶细胞的方法。 本发明还提供了抑制HCV融合并进入靶细胞的药剂。 本发明进一步提供了治疗患有HCV相关病症的受试者，用于预防受试者中的HCV感染以及用于在受试者中抑制HCV相关病症发作的方法。
-
-
搜索结果
3 条记录 (耗时 0.01 秒)
